TCM
BTAI icon

Triumph Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Triumph Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 1860
2026
Q1 		$1 Hold
1
– – ﹤0.01% 1835
2025
Q4 		$2 Buy
+1
New +$2 ﹤0.01% 1768

Other funds holding BTAI

FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Triumph Capital Management's BTAI Position: Q2 2026 in Review

Triumph Capital Management held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

Triumph Capital Management first reported a position in BTAI in Q4 2025 and has held it in 3 quarters since. The position peaked at $2 in Q4 2025. 3 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Triumph Capital Management held 1 share of BioXcel Therapeutics worth $1 as of Q2 2026.
  • Triumph Capital Management left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1860 holding.
  • Triumph Capital Management first reported a position in BioXcel Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's BioXcel Therapeutics position peaked at $2 in Q4 2025.
  • 3 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.